TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01000311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib
Description: IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib
Description: IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV
Description: IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV
Description: IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV
Description: IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV
Description: IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
Study: NCT03079323

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PART-trial
Description: Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
Study: NCT04070131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horse-Assisted Rehabilitation
Description: One hour weelky session of hippotherapy.
Study: NCT02844751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [StroMed + platelet rich plasma (PRP)]
Description: \[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Study: NCT04420351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase thrombolysis
Description: The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin;Clopidogrel
Description: The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
Study: NCT00818519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/Drospirenone (YAZ, BAY86-5300)
Description: 20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tablet
Study: NCT02181179

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
Study: NCT02844751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [StroMed + platelet rich plasma (PRP)]
Description: \[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [PRP] platelet rich plasma
Description: Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [PRP] platelet rich plasma
Description: Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
Study: NCT02780869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST Bellows

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable gelatin sponge, USP with thrombin
Study: NCT00367380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 413ABM
Description: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 414WRR
Description: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 418JAL
Description: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
Study: NCT01790659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396
Description: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: Paromomycin alone
Study: NCT03639545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: The patients receive empagliflozin (25 mg daily) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: The patients receive empagliflozin (25 mg daily) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The patients receive metformin (2000 mg daily) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The patients receive metformin (2000 mg daily) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin/Metformin
Description: The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
Study: NCT01877629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968 500 mg tablet
Description: ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968 500 mg tablet
Description: ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968 250 mg capsule
Description: ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968 250 mg capsule
Description: ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
Study: NCT03639545

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The patients receive for 12 weeks.
Study: NCT04235894

Intervention type: DRUG
Intervention: Propofol
Description: Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
Study: NCT00440037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
Study: NCT02482324

Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1a
Description: Mast cell stabilizer

Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1a
Description: Mast cell stabilizer

Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1b
Description: anti-inflammatory

Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1b
Description: anti-inflammatory

Intervention type: DEVICE
Group type: OTHER
Intervention: Dry Powder Inhaler
Description: The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Dry Powder Inhaler
Description: The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
Study: NCT02954809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning bright light therapy
Description: Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim light
Description: Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
Study: NCT02985086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoxitin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoxitin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin/misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin/misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin/misoprostol
Study: NCT03091842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo supervised CARE program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo supervised TARE program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo home-based stretching program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive instructional DVD and booklet of the flexibility exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03588195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Nerve Electro-Stimulation
Description: Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Electro-Stimulation
Description: Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
Study: NCT03615404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-DCs with GM-CSF
Description: CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td (tetanus toxoid)
Description: Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
Study: NCT03536767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG10
Description: AG10 800mg twice daily, oral administration
Study: NCT04008004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EDP-514

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EDP-514
Study: NCT04526262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic resonance guided focused ultrasound BBB disruption
Description: The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
Study: NCT01150942

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine
Description: 3 times, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JE vaccine
Description: 3 times, IM
Study: NCT01461187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise during pregnancy
Description: supervised aerobic physical exercises twice a week.
Study: NCT03584412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT OPEN
Description: Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
Study: NCT02234921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRibble Vaccine
Description: DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccinations
Description: Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
Study: NCT03984786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment Interview
Description: An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment Interview
Description: An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance
Description: Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance
Description: Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
Study: NCT03584412

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list control
Description: Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
Study: NCT03039959

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT03266601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon α-2b Spray
Description: Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
Study: NCT01190631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof IQ (SN60WF) IOL
Description: Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
Study: NCT04419753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention focus walking training
Description: Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention focus walking training
Description: Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention focus walking training
Description: Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
Study: NCT02152605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg